Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
This is a research study that plans to learn more about the safety and tolerability of an
investigational drug called Olaparib, in combination with radiation therapy and cetuximab.
Hypothesis: Intensity modulated radiotherapy with concurrent C225 and Olaparib represents a
feasible, biologically-based alternative to standard chemoradiation, with acceptable
toxicity, for treatment of locally-advanced HNSCC in patients having a ≥ 10 pack-year smoking
history.